Dr. Reddy’s Laboratories announced the launch of Bupropion HCl Extended-Release Tablets, the generic version of GlaxoSmithKline‘s Wellbutrin SR

Wellbutrin SR is an aminoketone antidepressant indicated for the treatment of major depressive disorder (MDD). Bupropion HCl is presumed to exert its effects through noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine, and does not inhibit the reuptake of serotonin; it does not inhibit monoamine oxidase. 

Related Articles

Bupropion HCl Extended-Release Tablets are available as 100mg, 150mg, and 200mg strengths in 60-, 100-, and 500-count bottles. 

For more information call (866) 733-3952 or visit DrReddys.com.